GLP-1TRZ is a synthetic research peptide studied for its activity as a dual GIP/GLP-1 receptor agonist — engaging two distinct incretin receptor pathways within a single molecule. It sits between single-receptor compounds like Semaglutide and the newer triple-agonist GLP-3RTA, making it a common middle point of comparison in incretin research. Helix Bio supplies GLP-1TRZ as a lyophilized powder intended strictly for laboratory and preclinical research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application, and it is a separate product from FDA-approved branded medications.
HPLC certified
Independent analysis
Highest standard
Full traceability
GLP-1TRZ is studied as a dual incretin receptor agonist — a peptide engineered to engage both the GIP receptor and the GLP-1 receptor, rather than the GLP-1 receptor alone. That distinguishes it from earlier single-target compounds like semaglutide and liraglutide, and it's part of why researchers use it as a comparison point when characterizing what a second (or third, in GLP-3RTA's case) receptor target adds mechanistically to incretin pharmacology.
Helix Bio's GLP-1TRZ is supplied as a lyophilized (freeze-dried) powder — a synthetic peptide manufactured under controlled laboratory conditions. Lyophilization extends shelf stability prior to reconstitution, which is useful for labs running studies over an extended timeline rather than using a full vial at once.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying dual incretin receptor pharmacology, GIP/GLP-1 signaling, or metabolic research models.
GLP-1TRZ occupies a useful middle position in incretin research — it adds a second receptor target on top of the GLP-1-only compounds, without the added complexity of a third. That makes it a natural comparator whether your study design is benchmarking against semaglutide on one side or GLP-3RTA on the other. Helix Bio manufactures its GLP-1TRZ domestically, backs every batch with purity testing, and issues documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for a well-characterized dual-agonist peptide with a clear paper trail, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting, and it is not a substitute for any FDA-approved medication.
| Field | Detail |
|---|---|
| Product Name | GLP-1TRZ |
| Category | Research Peptide — Dual GIP/GLP-1 Receptor Agonist |
| Form | Lyophilized powder |
| Purity | High-purity, batch-verified — see current lot's Certificate of Analysis for the exact figure |
| Appearance | White to off-white lyophilized powder |
| Storage (unreconstituted) | Store frozen, protected from light |
| Packaging | Sealed glass vial, tamper-evident packaging |
| Research Use | Laboratory / in vitro / preclinical research only — not for human or animal use |
| Manufacturer | Domestically produced (USA) |
| Quality | Third-party purity testing performed per batch |
| Lot Testing | HPLC and mass spectrometry verification |
| Country of Origin | United States |
GLP-1TRZ is studied across a few overlapping areas of metabolic and endocrine research:
The dual GIP/GLP-1 agonist class has a clinical trial record built primarily on Eli Lilly's SURMOUNT program (weight management) and SURPASS program (type 2 diabetes), both widely cited in comparative incretin-class research. Compounds in this class also appear as active ingredients in FDA-approved branded prescription medications. GLP-1TRZ is a separate, research-grade product — it is manufactured and labeled for laboratory research only and is not the same product, formulation, or delivery system as any approved drug. Nothing here should be read as equivalent to, a substitute for, or off-label guidance regarding any approved medication.
Purity is the first thing serious researchers check, and it's the first thing worth being transparent about. Helix Bio's GLP-1TRZ is manufactured in a controlled laboratory environment and tested by a third party using high-performance liquid chromatography (HPLC) and mass spectrometry — the two standard methods for confirming peptide identity and purity in the research supply chain. Each batch is issued its own Certificate of Analysis (COA), so purity isn't something you have to take on faith; you can review the documentation for the specific lot you receive. If a vendor can't produce a COA for the batch in your hand, that's worth treating as a red flag — for GLP-1TRZ or any research peptide.
Handling in our facility follows accepted good manufacturing practice for research-use compounds: peptides are processed to limit contamination, packaged in sealed, tamper-evident vials, and shipped in a way that protects the lyophilized powder from temperature swings and light exposure during transit.
GLP-1TRZ ships in a sealed, tamper-evident vial packaged to protect the lyophilized powder in transit. Because peptide stability can be affected by heat, orders are packed with insulation appropriate to the season and route. Exact carriers, transit times, and packaging materials can vary by order — check Helix Bio's shipping policy page for current specifics before ordering.
GLP-1TRZ sold by Helix Bio is intended strictly for in vitro laboratory and preclinical research use. It is not a drug, dietary supplement, cosmetic, or food product, and this specific research-grade material is not approved by the FDA or any regulatory body for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease or condition. It is a distinct product from any FDA-approved medication and must not be treated as interchangeable with, or a substitute for, an approved prescription drug. This product must not be administered to humans or animals outside of a properly licensed research facility. Nothing on this page constitutes medical advice, and no statement here should be interpreted as a therapeutic or health claim. By purchasing this product, the buyer confirms they are a qualified researcher, laboratory, or institution acquiring it for lawful research purposes only, and accepts full responsibility for compliance with all applicable local, state, and federal regulations governing research chemicals.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Amycretin is a peptide and orforglipron is not. How that chemistry explains the formulations, trial results, and approval status of both GLP-1 pills.
Five peptide sellers got FDA warning letters in September 2026. See who was named, why the research label failed, and the full 2026 enforcement timeline.
In July 2026, the FDA's advisory committee recommended 6 peptides for the 503A bulk list. None are on it yet. What the vote changed and what it didn't.
